Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective.

Authors:
Nervo A; Retta F; Ragni A; Piovesan A; Gallo M and 1 more

Journal:
Cancer Manag Res

Publication Year: 2022

DOI:
10.2147/CMAR.S340967

PMCID:
PMC9584766

PMID:
36275786

Journal Information

Full Title: Cancer Manag Res

Abbreviation: Cancer Manag Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure Dr Alessandro Piovesan reports personal fees from EISAI, personal fees from AAA, personal fees from Eli Lilly Italy, outside the submitted work. Dr Marco Gallo reports personal fees from EISAI, personal fees from AAA, during the conduct of the study. The authors report no conflicts of interest in this work."

Evidence found in paper:

"This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025